You are here:

fosaprepitant dimeglumine (IVEmend 150mg)

Advice

following an abbreviated submission:

fosaprepitant dimeglumine (IVEmend 150mg®) is accepted for use within NHS Scotland.

Indication under review: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults.
IVEmend 150 mg is given as part of a combination therapy.

Fosaprepitant 150mg is not recommended for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults, as SMC has previously not recommended both fosaprepitant iv and aprepitant capsules for this indication.

Drug Details

Drug Name: fosaprepitant dimeglumine (IVEmend 150mg)
SMC Drug ID: 678/11
Manufacturer: MSD
Indication: prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults. IVEmend 150 mg is given as part of a combination therapy.
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 7 March 2011

Back